Fierce Biotech reports on new study from BIO and BioMedTracker that shows the overall success rate for drugs moving through clinical trials to FDA approval dropped to one in ten, from a previous rate of one in five or six. The period covered by the study is 2003-2010.
Oncology drugs were hit hardest (no surprise if you watch clinical trial results). Surprisingly (to me), large molecule drugs are twice as likely to be approved as small molecules (more me-too's I guess).
"This groundbreaking study highlights the depth and breadth of risk inherent in the drug development process more comprehensively than any other previous study," said Alan Eisenberg, executive vice president of emerging companies and business development at BIO.
Insert your own lobbying effort [here] calling for more R&D grants and supports for the biotech industry. I may make fun - but do think support announced by Obama administration for increased biotech investment is good idea. The trend described here does need to be reversed - policies that boost innovation and support greater R&D should help.
Posted by Bruce Lehr Feb 15th 2011.